Close
Nordic 9Nordic 9

Monograph Capital (investor - Venture Capital)

United Kingdom monograph.bio
See something wrong or missing? Let us know
Offices:London

Monograph Capital is a life sciences venture firm. from the UK

Average round investment:56M USD
Average number per year:1.0
Distribution: 2025 (1)2023 (1)2021 (1)
Portfolio companies: United Kingdom Maxion TherapeuticsUnited Kingdom Aviado Bio
Mostly invests in: United Kingdom United Kingdom (3) Pharma (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Monograph Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Monograph Capital

Name Criteria
United States Bicycle Day Ventures
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
Hong Kong CR-CP Life Science Fund
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
United States Green Sands Equity
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
United States New Leaf Venture Partners
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
United Kingdom Rosetta Capital
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
United States Venrock
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
China GT Healthcare Capital
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
United States Rick Klausner
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
Japan UTokyo IPC
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
United Kingdom Leafy Tunnel
79%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
Top